BRCA2 and cancer: | ClinicalTrials.gov), and their applicability in vitro with human cancer cell lines32–34 and in vivo with a BRCA2 xenograft mouse model35 suggest that continued pursuit of RECQ pharmacological modulation to combat cancer in preclinical models may translate to efficacious strategies in the clinic.